With the boom of CBD products, the golden question is if CBD oil is all a placebo effect.
CBD comes in different forms nowadays, from tinctures to bath bombs. With many benefits, disease-specific and overall wellness, CBD is ruling the market with its different versions.
When it comes to CBD for health conditions, there are sprays, creams and most widely used and available – CBD oil.
The CBD revolution started with identifying its potential to cure a rare form of epilepsy, Dravid’s syndrome. Further studies and researches paved the way for understanding the benefits of CBD for different conditions. Today, CBD oil is the biggest seller in the market and it comes in different concentrations.
All the hype and news about CBD has raised doubts about CBD’s credibility too. Many still are in the dilemma whether CBD can actually cure or if it is all a placebo scam. Social media cells/online forums are filled with people explaining with their stories to answer this question. Before giving a clear cut answer, let’s discuss what makes people think CBD is the placebo effect.
What is CBD
Cannabidiol or CBD is one of the many phytocannabinoids present in the cannabis plant. Constituting up to 40% of the total plant extract, this phytocannabinoid is found to have many health benefits. What makes it more suitable to add to the daily routine is the fact that it doesn’t get you high.
THC, on the other hand, is also a well-known compound from the cannabis plant. THC is the compound that is responsible for the “high” experience while smoking up. It also has health benefits like pain relief but it is also psychoactive.
When we talk about medical marijuana, we are generally considering CBD with no THC. Since THC is also an active constituent of the cannabis plant, a limit of 0.03% is set for medical marijuana products. CBD products with less than 0.03% of THC make the psychoactive effects of THc practically ineffective. So, do check the THC content before making a purchase.
There are many who claim legalization of CBD is another scam in the name of medicine to smoke up. This is totally wrong since the category of medical marijuana products isn’t capable of fulfilling the recreational purpose.
Health Benefits of CBD
CBD helps with different health conditions and also promotes overall wellness. The major health benefits are shown to be in the field of:
- Pain relief
- Anxiety relief
- Weight loss
Pain relief is one of the major areas where CBD is very efficient. CBD, with their anti-inflammatory properties, helps alleviate pain due to arthritis and any other chronic pain. In addition to reducing inflammation, CBD also regulates the perception of pain in the brain.
Anxiety is a growing social issue that is affecting the quality of life for many. CBD helps with relieving anxiety issues and is helping improve life for many. CBD does this by interacting with the endocannabinoid system. You can read more about how CBD helps with anxiety-related issues here.
CBD products are a helpful way to improve the quality of sleep, have a boost of energy and keep yourself relaxed from the stress. CBD also helps women with menstrual cramps, postpartum depression, and related issues.
CBD for the pets has shown immense potential in helping the furry ones with pain, depression and other behavioral issues. The success stories from happy customers of CBD speaks for itself about the benefits of CBD for pets.
How Does CBD Do It All?
CBD has shown different properties that are effective in treating a wide variety of the health issues mentioned above. Some of these properties include and are not limited to:
From an attempt to study the effects of cannabis on the human body, the endocannabinoid system and its working came into light. The endocannabinoid system is present in almost all organisms. This system is made up of endocannabinoids, receptor proteins and is spread throughout the nervous system. Later on, it was found the endocannabinoid system has an active role when it comes to almost every disease.
Cannabinoids are active constituents in the cannabis plant. Out of several cannabinoids present in the cannabis plant, Cannabidiol or CBD is shown to have great benefits when it comes to activating the endocannabinoid system in a natural way. CBD indirectly affects the endocannabinoid system by activating the cannabinoid receptors by regulating the amount endocannabinoids in the body.
This interaction with the endocannabinoid system helps to regulate different physiological activities like appetite, mood, sleep and so on. The major problem when it comes to mental illness is the lack of neural activity in different parts of the brain. CBD helps to promote the neurogeneration and helps to cope up with the situation.
Is CBD a Placebo?
For one, there are many cases like epilepsy where CBD has shown clear evidence of helping with the seizures. Different studies show the analgesic effect of CBD on animal models. There should be more clinical trials and studies needed to prove the exact mechanism of how CBD works in the biological system.
Anything can be a placebo if we have thorough trust in something. CBD is no different in this regard. But, that doesn’t disregard the efficiency of this natural compound in helping humans with their health. There are a few studies like this one where people were administered with CBD and also tested for the placebo. The results show the positive effects of CBD in this case. More such studies need to be carried out to prove the efficiency of CBD scientifically.
To wrap up,
I would say, trust in the medication you take. CBD has many benefits and no or minimal side effects compared to its alternatives. CBD has been used in ancient times for medicinal purposes. It may be a while the research catches up with a finding of the exact mechanism but that should not limit bringing the help to whoever needs it now.
Good cbd carts in LA?
Live in LA so have access to all the dispensaries. Looking for a good cart recommendation as it seems to be the only method that has an effect for me before bed. Currently using a brand called “cannabis by design” 18:1 ratio and like it but I feel like there are better brands out there?
There may still be hope for the ‘not perfect’ USDA final rule on hemp
United States Department of Agriculture’s finalized hemp regulations, which were published on January 15, evoked a variety of responses f…
United States Department of Agriculture’s finalized hemp regulations, which were published on January 15, evoked a variety of responses from those invested in the industry. In a previous blog post, we covered some of the changes between the final rule and the interim final rule (IFR) that have industry leaders celebrating. However, the final rule might be more of a mixed bag overall.
Although it includes some provisions that are expected to benefit the hemp industry, there are others that may leave industry leaders disappointed, including the requirements for harvest samples to come from hemp flowers, for total tetrahydrocannabinol (THC) testing, and for testing to occur in labs certified by the Drug Enforcement Administration (DEA).
“It does not seem to be clear that it is a definite improvement over the interim final rule but that it is not perfect. It does not go as far as some of the key things we requested,” Jonathan Miller told Marijuana Moment. Miller is the general counsel for the U.S. Hemp Roundtable.
Industry stakeholders reportedly encouraged the United States Department of Agriculture (USDA) to allow pre-harvest samples to come from a greater part of the plant or the whole plant instead of just the flower. The USDA did not include this change in its final rule. Instead, it claims that the flower is the most appropriate place to sample because THC is concentrated there.
Under the final rule, pre-harvest samples must still come from the cannabis flower. However, this requirement has been modified slightly. When the final rule goes into effect on March 22, the samples can be taken from about five to eight inches from the main stem, terminal bud, or central cola of the flowering top of the plant.
Another request made by industry stakeholders was for hemp crops to be tested for delta-9 THC instead of total THC content. Delta-9 THC is the main psychoactive component in cannabis — the component that can make people feel high. Total THC includes the possible conversion of tetrahydrocannabinolic acid (THCA) into THC.
Some reportedly believe that the total THC better represents the sample’s potential to get someone high because it accounts for the cannabinoids that could be activated with heat when the product is consumed through vaping, smoking , or cooking. However, THCA is not psychoactive, and not all products that may be made from hemp would result in THCA being converted to delta-9 THC.
Unfortunately, the USDA maintained that hemp must be tested for total THC content, and that the THC concentration for a legal hemp crop must be below 0.3%.
Perhaps the biggest disappointment to industry stakeholders is that the USDA’s final rule did not change the requirement for hemp testing to occur only at labs certified by the DEA.
“Registration is necessary because laboratories could possibly handle cannabis that tests above 0.3% THC on a dry weight basis, which is, by definition, marijuana and a Schedule 1 controlled substance,” the final rule states.
However, there are not enough qualifying labs available to efficiently handle the number of hemp tests needed in this growing industry, a fact that was acknowledged in the final rule.
The final rule adds, “[S]ince the IFR was published, numerous laboratories have applied for registration and DEA is working diligently to process these requests.”
In the meantime, the USDA is delaying the enforcement of this rule. It was first delayed in 2020, and the final rule extended this delay until December 2022.
Although the USDA’s final rule did include some positive steps, it also lacked several important changes that industry stakeholders were hoping to see.
“USDA seems to have declined to act upon many of the comments submitted, particularly concerning sampling uncertainty, DEA labs and Total THC among others,” Herrick Fox reportedly told Hemp Industry Daily. Fox is the owner of Meristem Farms and a former USDA rulemaker.
“Many are justifiably disappointed by the DEA’s continued (and in some ways expanded) role in the agricultural hemp program,” said Shawn Hauser in a press release. Hauser is a partner and chair of the Hemp and Cannabinoids Department at Vincente Sederberg LLP.
The USDA released its final rule in the last week of the Trump administration, but some industry leaders remain hopeful that the situation regarding hemp regulations may change under the Biden administration.
“We anticipate, as is customary of new administrations, that this rule will be one of many that will be frozen on the first day of the Biden administration,” Larry Farnsworth, a spokesperson for the National Industrial Hemp Council, reportedly told Marijuana Moment.
“We look forward to working through these issues with the incoming Biden administration,” he added.
Alginate Affects Bioactivity of Chimeric Collagen-Binding LL37 Antimicrobial Peptides Adsorbed to Collagen-Alginate Wound Dressings
Chronic infected wounds cause more than 23,000 deaths annually. Antibiotics and antiseptics are conventionally used to treat infected wounds; however, they can be toxic to mammalian cells, and their use can contribute to antimicrobial resistance. Antimicrobial peptides (AMPs) have been utilized to address the limitations of antiseptics and antibiotics. In previous work, we modified the human AMP LL37 with collagen-binding domains from collagenase (cCBD) or fibronectin (fCBD) to facilitate…
Chronic infected wounds cause more than 23,000 deaths annually. Antibiotics and antiseptics are conventionally used to treat infected wounds; however, they can be toxic to mammalian cells, and their use can contribute to antimicrobial resistance. Antimicrobial peptides (AMPs) have been utilized to address the limitations of antiseptics and antibiotics. In previous work, we modified the human AMP LL37 with collagen-binding domains from collagenase (cCBD) or fibronectin (fCBD) to facilitate peptide tethering and delivery from collagen-based wound dressings. We found that cCBD-LL37 and fCBD-LL37 were retained and active when bound to 100% collagen scaffolds. Collagen wound dressings are commonly made as composites with other materials, such as alginate. The goal of this study was to investigate how the presence of alginate affects the tethering, release, and antimicrobial activity of LL37 and CBD-LL37 peptides adsorbed to commercially available collagen-alginate wound dressings (FIBRACOL Plus-a 90% collagen and 10% alginate wound dressing). We found that over 85% of the LL37, cCBD-LL37, and fCBD-LL37 was retained on FIBRACOL Plus over a 14-day release study (90.3, 85.8, and 98.6%, respectively). Additionally, FIBRACOL Plus samples loaded with peptides were bactericidal toward Pseudomonas aeruginosa, even after 14 days in release buffer but demonstrated no antimicrobial activity against Escherichia coli, Staphylococcus aureus, and Staphylococcus epidermidis. The presence of alginate in solution induced conformational changes in the cCBD-LL37 and LL37 peptides, resulting in increased peptide helicity, and reduced antimicrobial activity against P. aeruginosa. Peptide-loaded FIBRACOL Plus scaffolds were not cytotoxic to human dermal fibroblasts. This study demonstrates that CBD-mediated LL37 tethering is a viable strategy to reduce LL37 toxicity, and how substrate composition plays a crucial role in modulating the antimicrobial activity of tethered AMPs.
Keywords: Pseudomonas aeruginosa; alginate; antimicrobial peptide; collagen scaffold; collagen-binding domain; peptide delivery.
MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors
What are Some Major Factors to Keep in Mind When Buying CBD Vape Oil?
New York Small Business Cooperative License
Cannabis Sector Reverse Splits – The Good, The Bad, and The Ugly
Mama Cultiva & the Fight for Cannabis Legalization
New York Cannabis Distributor License
Investors in This Cannabis Stock Are Leaving $800 Million on the Table
What’s New With Cannabis Stocks for the Week Ending 01/15/21
What is Delta-8 THC? Everything You Need to Know
New York Cannabis Delivery License
The USDA Has Released Its Final Rule on Hemp Regulation
Cannabis Nursery in New York
Optical Coherence Tomography Findings in Cannabis Users
CBD News: Clint Eastwood files third suit against CBD companies, saying they’re falsely claiming endorsement
Virginia Subcommittee on Marijuana Forms to Debate Legalization Bill
MMJRecs What Does The 2020 Election Mean For Medical Marijuana?
New York’s Marijuana Cultivation License
The DEA Has Now Received Nearly Fifty Applications for Federal Cannabis Cultivation Licenses
USDA Issues Final Rule On Hemp
France’s “recreational” cannabis survey • New Mexico governor prioritizes legalization • California eases banking access • & more…
CBD News Roundup: FDA Provides Framework for Future CBD Research
High Times Greats: Robert Anton Wilson
New York’s Adult-Use Processor License
The Blinc Group Raises $1.5 Million
Hydrobuilder Holdings Raises $70 Million and Combines West Coast Hydroponics Chain with Online Retailer
Flashback Friday: Recollections of a Lady Dealer
EGF Theramed Raises $352,502 in First Tranche of Private Placement
Some Oddly Specific Predictions About Films You Should Keep an Eye Out For This Year
Subversive Closes Largest Cannabis SPAC With Jaz-Z As Chief Visionary Officer
Antioxidant Function of Phytocannabinoids: Molecular Basis of Their Stability and Cytoprotective Properties under UV-irradiation
News6 days ago
Pure Harvest Bolsters Corporate Team with Key Additions
Heartland5 days ago
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
Heartland1 week ago
Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer
Heartland1 week ago
Compared to Prescription Medication, Medical Cannabis Not Always Affordable Alternative
Heartland1 week ago
Novamind Appoints Chuck Rifici to its Board of Directors
Uncategorized5 days ago
MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors
Uncategorized1 week ago
Sundial Announces the Launch of Premium Concentrates Products Under its Top Leaf Brand
Heartland1 week ago
Can You Treat COVID-19 With CBD and Reduce Mortality Rates? A New Israeli Research Believes You Can!